

## ICMJE Form for Disclosure of Potential Conflicts of Interest

---

### Instructions

**The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.**

#### 1. Identifying information.

Enter your full name. If you are NOT the corresponding author please check the box "no" and a space to enter the name of the corresponding author in the space that appears. Provide the requested manuscript information. Double-check the manuscript number and enter it.

#### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes". The complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

#### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

#### 4. Other relationships.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

## ICMJE Form for Disclosure of Potential Conflicts of Interest

### Section 1. Identifying Information

1. Given Name (First Name)  
Simon
2. Surname (Last Name)  
TRAVIS
3. Effective Date (07-August-2008)  
30-September-2018
4. Are you the corresponding author?  Yes  No
5. Manuscript Title  
2018-2019 ECCO Annual Disclosure of potential conflicts of interest
6. Manuscript Identifying Number (if you know it)  
N/A

### Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

Complete each row by checking "No" or providing the requested information. **If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.**

| The Work Under Consideration for Publication  |                                     |                          |                            |                |            |     |
|---|-------------------------------------|--------------------------|----------------------------|----------------|------------|-----|
| Type  | No                                  | Money Paid to You        | Money to Your Institution* | Name of Entity | Comments** |     |
| 1. Grant  | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/>   |                |            | X   |
|   |                                     |                          |                            |                |            | ADD |
| 2. Consulting fee or honorarium   | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/>   |                |            | X   |
|   |                                     |                          |                            |                |            | ADD |
| 3. Support for travel to meetings for the study or other purposes   | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/>   |                |            | X   |
|   |                                     |                          |                            |                |            | ADD |
| 4. Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/>   |                |            | X   |
|   |                                     |                          |                            |                |            | ADD |
| 5. Payment for writing or reviewing the manuscript  | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/>   |                |            | X   |
|   |                                     |                          |                            |                |            | ADD |
| 6. Provision of writing assistance, medicines, equipment, or administrative support   | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/>   |                |            | X   |

## ICMJE Form for Disclosure of Potential Conflicts of Interest

| The Work Under Consideration for Publication |                                     |                          |                            |                |            |          |
|--|-------------------------------------|--------------------------|----------------------------|----------------|------------|----------|
| Type   | No                                  | Money Paid to You        | Money to Your Institution* | Name of Entity | Comments** |          |
|  |                                     |                          |                            |                |            | ADD      |
| 7. Other                                     | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/>   |                |            | X<br>ADD |

\* This means money that your institution received for your efforts on this study.

\*\* Use this section to provide any needed explanation.

### Section 3.

#### Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking "No" or providing the requested information. **If you have more than one relationship click the "Add" button to add a row. Excess rows can be removed by clicking the "X" button.**

| Relevant financial activities outside the submitted work |                                     |                                     |                            |                      |   |     |
|--|-------------------------------------|-------------------------------------|----------------------------|----------------------|---|-----|
| Type of Relationship (in alphabetical order)             | No                                  | Money Paid to You                   | Money to Your Institution* | Entity               | Comments  |     |
| 1. Board membership                                      | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | <input type="checkbox"/>   | IBD2020              | Director of Charity                               | X   |
| 1. Board membership                                      | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | <input type="checkbox"/>   | Truelove Foundation  | Director of Charity                               | X   |
| 1. Board membership                                      | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | <input type="checkbox"/>   | Crohn's Colitis Cure | Director of Charity                               | X   |
|  |                                     |                                     |                            |                      |   | ADD |
| 2. Consultancy   | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | <input type="checkbox"/>   | AbbVie               | None as ECCO President (Feb2012-14). Resumed 2014 | X   |
| 2. Consultancy   | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | <input type="checkbox"/>   | Centocor             | None as ECCO President (Feb2012-14)               | X   |
| 2. Consultancy   | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | <input type="checkbox"/>   | Schering-Plough      | None as ECCO President (Feb2012-14)               | X   |
| 2. Consultancy   | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | <input type="checkbox"/>   | Bristol Myers Squibb | None as ECCO President (Feb2012-14).Resumed 2014  | X   |
| 2. Consultancy   | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | <input type="checkbox"/>   | Chemocentryx Inc     | None as ECCO President (Feb2012-14)               | X   |
| 2. Consultancy   | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | <input type="checkbox"/>   | Cosmo technologies   | Resumed 2014                                      | X   |

## ICMJE Form for Disclosure of Potential Conflicts of Interest

| Relevant financial activities outside the submitted work |                          |                                     |                                     |                         |  |   |
|--|--------------------------|-------------------------------------|-------------------------------------|-------------------------|--|---|
| Type of Relationship (in alphabetical order)             | No                       | Money Paid to You                   | Money to Your Institution*          | Entity                  | Comments   |   |
| 2. Consultancy   | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Elan Pharma Inc         | None as ECCO President (Feb2012-14)                  | × |
| 2. Consultancy   | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Genentech               | None as ECCO President (Feb2012-14). Resumed 2014-   | × |
| 2. Consultancy   | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Giuliani                | None as ECCO President (Feb2012-14). Resumed 2014-15 | × |
| 2. Consultancy   | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Merck and co.           | None as ECCO President (Feb2012-14)                  | × |
| 2. Consultancy   | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Takeda                  | None as ECCO President (Feb2012-14). Resumed 2014-   | × |
| 2. Consultancy   | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Otsuka Pharmaceuticals  | None as ECCO President (Feb2012-14)                  | × |
| 2. Consultancy   | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | PDL Biopharma           | None as ECCO President (Feb2012-14)                  | × |
| 2. Consultancy   | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Pfizer Inc              | None as ECCO President (Feb2012-14). Resumed 2014-   | × |
| 2. Consultancy   | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Shire Pharma            | None as ECCO President (Feb2012-14). Resumed 2016-   | × |
| 2. Consultancy   | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Glenmark Pharma         | None as ECCO President (Feb2012-14)                  | × |
| 2. Consultancy   | <input type="checkbox"/> | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | Synthon Pharma          | 2013   | × |
| 2. Consultancy   | <input type="checkbox"/> | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | NPS                     | 2014-15  | × |
| 2. Consultancy   | <input type="checkbox"/> | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | Lilly                   | 2013-  | × |
| 2. Consultancy   | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Warner Chilcott         | not since 2011                                       | × |
| 2. Consultancy   | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Proximagen              | 2014   | × |
| 2. Consultancy   | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | VHsquared               | 2015-  | × |
| 2. Consultancy   | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Topivert                | 2015-  | × |
| 2. Consultancy   | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Ferring Pharmaceuticals | 2015-  | × |
| 2. Consultancy   | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Celgene                 | 2015-  | × |
| 2. Consultancy   | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | Glaxo SmithKline        | 2014-  | × |
| 2. Consultancy   | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | Takeda                  | 2014-  | × |
| 2. Consultancy   | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Amgen                   | 2016-  | × |

## ICMJE Form for Disclosure of Potential Conflicts of Interest

|                          |                          |                                     |                                     |                            |                                     |   |
|--------------------------|--------------------------|-------------------------------------|-------------------------------------|----------------------------|-------------------------------------|---|
| 2. Consultancy           | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Biogen                     | 2016-                               | X |
| 2. Consultancy           | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Enterome                   | 2017-                               | X |
| 2. Consultancy           | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Immunocore                 | 2017-                               | X |
| 2. Consultancy           | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Immunometabolism           | 2017-                               | X |
| 2. Consultancy           | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Bioclinica                 | 2017-                               | X |
| 2. Consultancy           | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Boehringer Ingelheim       | 2017                                | X |
| 2. Consultancy           | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Gilead                     | 2017-                               | X |
| 2. Consultancy           | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Grunenthal                 | 2017                                | X |
| 2. Consultancy           | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Janssen                    | 2017-                               | X |
| 2. Consultancy           | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Novartis                   | 2014-16                             | X |
| 2. Consultancy           | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Celgene                    | 2016-                               | X |
| 2. Consultancy           | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Receptos                   | 2016-                               | X |
| 2. Consultancy           | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | PharmOlam                  | 2017-                               | X |
| 2. Consultancy           | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | SigmoidPharma              | 2017-18                             | X |
| 2. Consultancy           | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Theravance                 | 2017-                               | X |
| 2. Consultancy           | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | SynDermix                  | 2018                                | X |
| 2. Consultancy           | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Arena                      | 2018                                | X |
| 2. Consultancy           | <input type="checkbox"/> | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | Vifor                      | 2018                                | X |
| <b>ADD</b>               |                          |                                     |                                     |                            |                                     |   |
| 3. Employment            | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Oxford University Hospital |                                     | X |
| 3. Employment            | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | University of Oxford       |                                     | X |
| <b>ADD</b>               |                          |                                     |                                     |                            |                                     |   |
| 4. Expert testimony      | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Santarus Inc               | None as ECCO President (Feb2012-14) | X |
| 4. Expert testimony      | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Cosmo Technologies         | EMA appeal for Budesonide MMX       | X |
| 4. Expert testimony      | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Tillotts Pharma            | None as ECCO President (Feb2012-14) | X |
| <b>ADD</b>               |                          |                                     |                                     |                            |                                     |   |
| 5. Grants/grants pending | <input type="checkbox"/> | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | Ferring                    |                                     | X |
| 5. Grants/grants pending | <input type="checkbox"/> | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | AbbVie                     |                                     | X |
| 5. Grants/grants pending | <input type="checkbox"/> | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | Schering-Plough            |                                     | X |
| 5. Grants/grants pending | <input type="checkbox"/> | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | Merck Sharpe & Dhome (MSD) |                                     | X |

## ICMJE Form for Disclosure of Potential Conflicts of Interest

|   |                          |                                     |                                     |                                   |  |   |
|---|--------------------------|-------------------------------------|-------------------------------------|-----------------------------------|--|---|
| 5. Grants/grants pending                                      | <input type="checkbox"/> | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | Procter & Gamble                  |  | × |
| 5. Grants/grants pending                                      | <input type="checkbox"/> | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | Warner Chilcott                   |  | × |
| 5. Grants/grants pending                                      | <input type="checkbox"/> | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | International Organisation of IBD |  | × |
| 5. Grants/grants pending                                      | <input type="checkbox"/> | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | Lilly                             |  | × |
| 5. Grants/grants pending                                      | <input type="checkbox"/> | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | UCB                               |  | × |
| 5. Grants/grants pending                                      | <input type="checkbox"/> | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | Vifor                             |  | × |
| 5. Grants/grants pending                                      | <input type="checkbox"/> | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | Norman Collisson Foundation       |  | × |
| 5. Grants/grants pending                                      | <input type="checkbox"/> | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | Buhlmann                          |  | × |
| 5. Grants/grants pending                                      | <input type="checkbox"/> | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | Takeda                            |  | × |
| 5. Grants/grants pending                                      | <input type="checkbox"/> | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | Janssen                           |  | × |
| <b>ADD</b>  |                          |                                     |                                     |                                   |  |   |
| 6. Payment for lectures including service on speakers bureaus | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | AbbVie                            | Only after University or academic invitation | × |
| 6. Payment for lectures including service on speakers bureaus | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Schering Plough                   | None since 2011                              | × |
| 6. Payment for lectures including service on speakers bureaus | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Centocor                          | None since 2010                              | × |
| 6. Payment for lectures including service on speakers bureaus | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Merck and co.                     | Only after University or academic invitation | × |
| 6. Payment for lectures including service on speakers bureaus | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Given Imaging                     | None since 2010                              | × |
| 6. Payment for lectures including service on speakers bureaus | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | UCB Pharma                        | None since 2009                              | × |
| 6. Payment for lectures including service on speakers bureaus | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Ferring Pharmaceuticals           | Only after University or academic invitation | × |
| 6. Payment for lectures including service on speakers bureaus | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Tillotts laboratories             | None since 2011                              | × |
| 6. Payment for lectures including service on speakers bureaus | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Shire                             | 2018   | × |
| 6. Payment for lectures including service on speakers bureaus | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Sanofi Aventis                    | None since 2011                              | × |
| 6. Payment for lectures including service on speakers bureaus | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Vifor                             | None since 2011                              | × |
| 6. Payment for lectures including service on speakers bureaus | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Takeda                            | 2014-  | × |
| 6. Payment for lectures including service on speakers bureaus | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Amgen                             | 2016-  | × |

## ICMJE Form for Disclosure of Potential Conflicts of Interest

|   |                                     |                                     |                                     |                         |   |     |
|---|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------|---|-----|
| 6. Payment for lectures including service on speakers bureaus               | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Biogen                  | 2016  | ×   |
|   |                                     |                                     |                                     |                         |   | ADD |
| 7. Payment for manuscript preparation                                       | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | <input type="checkbox"/>            | Ferring                 | None since 2010   | ×   |
|   |                                     |                                     |                                     |                         |   | ADD |
| 8. Patents (planned, pending or issued)                                     | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | <input type="checkbox"/>            |                         |   | ×   |
|   |                                     |                                     |                                     |                         |   | ADD |
| 9. Royalties  | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Wiley Blackwell         | Book  | ×   |
| 9. Royalties  | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Elsevier                | Book  | ×   |
| 9. Royalties  | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Oxford University Press | Book  | ×   |
|   |                                     |                                     |                                     |                         |   | ADD |
| 10. Payment for development of educational presentations                    | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Abbott Laboratories     | Booklets and slides 2010                                  | ×   |
| 10. Payment for development of educational presentations                    | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Procter & Gamble        | Booklets and slides 2009                                  | ×   |
| 10. Payment for development of educational presentations                    | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Warner Chiclcott        | Booklet 2011  | ×   |
|   |                                     |                                     |                                     |                         |   | ADD |
| 11. Stock/stock options   | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | <input type="checkbox"/>            |                         |   | ×   |
|   |                                     |                                     |                                     |                         |   | ADD |
| 12. Travel/accommodations/meeting expenses unrelated to activities listed** | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | AbbVie                  | Attendance at DDW   | ×   |
| 12. Travel/accommodations/meeting expenses unrelated to activities listed** | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | UEG                     | Attendance at UEGW  | ×   |
| 12. Travel/accommodations/meeting expenses unrelated to activities listed** | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | <input type="checkbox"/>            | Shire                   | Attendance at UEGW  | ×   |
|   |                                     |                                     |                                     |                         |   | ADD |
| 13. Other (err on the side of full disclosure)                              | <input type="checkbox"/>            | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | Schering Plough         | Part salary for a nurse involved in therapeutic education | ×   |
| 13. Other (err on the side of full disclosure)                              | <input type="checkbox"/>            | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | Procter & Gamble        | Part salary for a nurse involved in therapeutic education | ×   |
| 13. Other (err on the side of full disclosure)                              | <input type="checkbox"/>            | <input type="checkbox"/>            | <input checked="" type="checkbox"/> | MSD                     | Part salary for a nurse involved in therapeutic education | ×   |

## ICMJE Form for Disclosure of Potential Conflicts of Interest

|  |                          |                          |                                     |                     |   |            |
|--|--------------------------|--------------------------|-------------------------------------|---------------------|---|------------|
| 13. Other (err on the side of full disclosure) | <input type="checkbox"/> | <input type="checkbox"/> | <input checked="" type="checkbox"/> | Vifor               | Part salary for a nurse involved in therapeutic education     | ×          |
| 13. Other (err on the side of full disclosure) | <input type="checkbox"/> | <input type="checkbox"/> | <input checked="" type="checkbox"/> | Abbott Laboratories | Unrestricted educational grant for lymphatic resaearch        | ×          |
| 13. Other (err on the side of full disclosure) | <input type="checkbox"/> | <input type="checkbox"/> | <input checked="" type="checkbox"/> | Procter & Gamble    | Unrestricted educational grant                                | ×          |
| 13. Other (err on the side of full disclosure) | <input type="checkbox"/> | <input type="checkbox"/> | <input checked="" type="checkbox"/> | PDL BioPharma       | Unrestricted educational grant for burden of disease research | ×          |
| 13. Other (err on the side of full disclosure) | <input type="checkbox"/> | <input type="checkbox"/> | <input checked="" type="checkbox"/> | Takeda              | Part salary for a nurse involved in therapeutic education     | ×          |
| 13. Other (err on the side of full disclosure) | <input type="checkbox"/> | <input type="checkbox"/> | <input checked="" type="checkbox"/> | ICHOM               | Chair of global working group on IBD outcome measures         | ×          |
|  |                          |                          |                                     |                     |   | <b>ADD</b> |

\* This means money that your institution received for your efforts.

\*\* For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

### Section 4.

#### Other relationships

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

- No other relationships/conditions/circumstances that present a potential conflict of interest
- Yes, the following relationships/conditions/circumstances are present (explain below):

The UCEIS© is freely available for use, acknowledging that the copyright of the terminology is registered to Watson Laboratories, NJ, successors in interest to Warner Chilcott Pharmaceuticals. All authors gave freely of their time.

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Hide All Table Rows Checked 'No'

SAVE



## ICMJE Form for Disclosure of Potential Conflicts of Interest

---

### Evaluation and Feedback

Please visit <http://www.icmje.org/cgi-bin/feedback> to provide feedback on your experience with completing this form.